IPIX is still at the stage where they have to play by the rules put down by the FDA, CDC, and any and all other federal agencies.
Why?
To make sure they don't give those agencies a chance to shut down IPIX which in turn would doom Brilacidin.
But the groundwork laid by the revelation of the viral properties regarding CV19 by GMU last night, the broad spectrum properties laid down by Rutgers and which we will see in a peer review in the near future, the upcoming presentation to the DOD Biodefense Research convention, and the results of the P2 human trial currently being wrapped up should put Brilacidin on the map of medicine, major media, and governments world wide.
The foundation has been laid to make Brilacidin a broad spectrum platform drug as it has now passed investigations by government labs showing its antiviral, antibiotic (clinical trial results proved its effectiveness), and anti-inflammatory properties. It has exhibited properties not even imagined by medicine IMO as to almost limitless advantages with a super strong safety profile and which should be able to be delivered thru a number of delivery systems so that the most advantageous system can be prescribed for each condition.
The post earlier today by farrell made clear in plain language what new info was released at the GMU presentation yesterday and this is only now SLOWLY being absorbed by not only the medical profession but the world in general. Most of us on this board would not have gleaned the pearls in last night's presentation if farrell hadn't stated them in layman's terms for us. Here is a copy of his post and the new data released last night:
New information at AVS :
Brilacidin is effective against all Covid 19 strains tested including the Delta variant.
Brilacidin has a biologic effect against Alpha viruses {encephalitis} and Bunyaviris {Rift Valley Fever}
Brilacidin inhibits pulmonary fibroblasts
Brilacidin's anti-inflammatory effects are confirmed
" Inhibition appears to impact viral integrity in a manner that interferes with entry and/or early
post-entry steps
• Inhibition extends to different strains of SARS-CoV-2 (alpha, beta, gamma and delta strain
assessments are planned)
• Synergistic activity with remdesivir without any apparent increase in toxicity
• Cell type independent inhibition of SARS-CoV-2 (Calu-3, Caco-2, primary lung fibroblasts)"
GLTA Farrel
The above news is mind boggling in the world of Covid19 but next to nobody is yet aware of it or pressing for the results of the phase 2 trial be rushed so that Brilacidin can be given EUA status and start saving lives from day 1 !!
But make no mistake, some major BPs are following all these presentations meticulously and they realize by now the breadth and value of the Brilacidin platform. We didn't see a great jump in the stock price today, but I can damn well guarantee that the value of the Brilacidin platform and IPIX shot up billions today in those BPs knowing what they will have to pony up to acquire any part of B or IPIX.
Once trial results are published and the muzzle is taken off broadcasting the abilities of Brilacidin to the world (should be only 6-8 weeks IMO), IPIX flies.
For those worrying about whether a US govt agency or the government as a whole would try and stop Brilacidin to protect BP interests, the phase 2 being mainly conducted in Russia pretty much brought that threat to a screeching halt.
I don't believe the only BPs making very serious overtures to IPIX are solely from the USA. There are other BPs worldwide that are large, well-funded, and would love to get their hands on IPIX/B/K. IPIX is not the traditional small bio startup going to BP and asking for any crumbs they may throw our way, they are going as the owner of science far beyond anything else on the market today and which should result in tens to hundreds of billions of dollars in revenue.
I believe the presentation last night was a mic drop moment for the virologists listening and Brilacidin is the new wonder drug most of them will want to be working on or their company be investigating.
New day, new game, and IPX is the new sheriff in town. YEE HAW!!
Why?
To make sure they don't give those agencies a chance to shut down IPIX which in turn would doom Brilacidin.
But the groundwork laid by the revelation of the viral properties regarding CV19 by GMU last night, the broad spectrum properties laid down by Rutgers and which we will see in a peer review in the near future, the upcoming presentation to the DOD Biodefense Research convention, and the results of the P2 human trial currently being wrapped up should put Brilacidin on the map of medicine, major media, and governments world wide.
The foundation has been laid to make Brilacidin a broad spectrum platform drug as it has now passed investigations by government labs showing its antiviral, antibiotic (clinical trial results proved its effectiveness), and anti-inflammatory properties. It has exhibited properties not even imagined by medicine IMO as to almost limitless advantages with a super strong safety profile and which should be able to be delivered thru a number of delivery systems so that the most advantageous system can be prescribed for each condition.
The post earlier today by farrell made clear in plain language what new info was released at the GMU presentation yesterday and this is only now SLOWLY being absorbed by not only the medical profession but the world in general. Most of us on this board would not have gleaned the pearls in last night's presentation if farrell hadn't stated them in layman's terms for us. Here is a copy of his post and the new data released last night:
New information at AVS :
Brilacidin is effective against all Covid 19 strains tested including the Delta variant.
Brilacidin has a biologic effect against Alpha viruses {encephalitis} and Bunyaviris {Rift Valley Fever}
Brilacidin inhibits pulmonary fibroblasts
Brilacidin's anti-inflammatory effects are confirmed
" Inhibition appears to impact viral integrity in a manner that interferes with entry and/or early
post-entry steps
• Inhibition extends to different strains of SARS-CoV-2 (alpha, beta, gamma and delta strain
assessments are planned)
• Synergistic activity with remdesivir without any apparent increase in toxicity
• Cell type independent inhibition of SARS-CoV-2 (Calu-3, Caco-2, primary lung fibroblasts)"
GLTA Farrel
The above news is mind boggling in the world of Covid19 but next to nobody is yet aware of it or pressing for the results of the phase 2 trial be rushed so that Brilacidin can be given EUA status and start saving lives from day 1 !!
But make no mistake, some major BPs are following all these presentations meticulously and they realize by now the breadth and value of the Brilacidin platform. We didn't see a great jump in the stock price today, but I can damn well guarantee that the value of the Brilacidin platform and IPIX shot up billions today in those BPs knowing what they will have to pony up to acquire any part of B or IPIX.
Once trial results are published and the muzzle is taken off broadcasting the abilities of Brilacidin to the world (should be only 6-8 weeks IMO), IPIX flies.
For those worrying about whether a US govt agency or the government as a whole would try and stop Brilacidin to protect BP interests, the phase 2 being mainly conducted in Russia pretty much brought that threat to a screeching halt.
I don't believe the only BPs making very serious overtures to IPIX are solely from the USA. There are other BPs worldwide that are large, well-funded, and would love to get their hands on IPIX/B/K. IPIX is not the traditional small bio startup going to BP and asking for any crumbs they may throw our way, they are going as the owner of science far beyond anything else on the market today and which should result in tens to hundreds of billions of dollars in revenue.
I believe the presentation last night was a mic drop moment for the virologists listening and Brilacidin is the new wonder drug most of them will want to be working on or their company be investigating.
New day, new game, and IPX is the new sheriff in town. YEE HAW!!
11
